Loading
The 2001 follow-up showing that the gene-expression groups of breast cancer predict how patients fare, with the basal-like group doing worst; it made the subtypes clinical rather than descriptive.
Sørlie, Perou, Tibshirani, Aas and colleagues analysed 85 cDNA microarray experiments representing 78 cancers, three fibroadenomas and four normal breast tissues by hierarchical clustering. As reported earlier, the cancers separated into a basal epithelial-like group, an ERBB2-overexpressing group and a normal breast-like group; the luminal, oestrogen receptor-positive group divided into at least two subgroups with distinct profiles. The subtypes were robust to two gene sets (456 intrinsic clones and an outcome-correlated set). In a subcohort of locally advanced cancers treated uniformly in a prospective study, outcomes differed significantly by group, with a poor prognosis for the basal-like subtype and a difference between the two oestrogen receptor-positive groups.
The first evidence that the basal-like group is not just biologically distinct but clinically dangerous, the observation that triple-negative outcome studies of 2007 confirmed in the clinic.
Shares Molecular portraits of human breast tumours, Charles M. Perou, Proceedings of the National Academy of Sciences, PAM50 / intrinsic subtypes and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares PAM50 / intrinsic subtypes, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.